Clinical trial
An Observational Clinical Study to evalUate the Effectiveness of Bosentan Therapy in Patients With Systemic scleRosis and Progressive Digital ulcEr Disease.
NCT05168215 is registered in ClinicalTrials.gov with Elpen Pharmaceutical Co. Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Observational Clinical Study to evalUate the Effectiveness of Bosentan Therapy in Patients With Systemic scleRosis and Progressive Digital ulcEr Disease.
- Lead sponsor
- Elpen Pharmaceutical Co. Inc.
- Phase
- Observational
- Overall status
- Unknown status
- Start date
- January 1, 2022
- Completion date
- June 1, 2024
- Enrollment
- 300 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
autoimmune diseases, diffuse cutaneous systemic sclerosis, digital ulcer, reynold syndrome, scleroderma